India-based generic drug manufacturer Wockhardt (BSE: 532300) is making its entry into the Middle East and North Africa (MENA) region with a new facility in Dubai.
The Mumbai-headquartered firm, which has manufacturing plants in India, the UK, Ireland, France and the USA, says the $40-million site will be used to make antibiotics for export, primarily to mature markets in Europe and the USA.
The self-contained factory, spread over 10,000 square meters, will focus initially on developing a therapy targeting so-called ‘superbugs’.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze